Oppenheimer Holdings Inc. reaffirmed their outperform rating on shares of Axovant Sciences Ltd (NYSE:AXON) in a research report sent to investors on Friday, April 14th. They currently have a $26.00 price target on the biotechnology company’s stock, up from their prior price target of $20.00.
Other analysts have also recently issued research reports about the stock. HC Wainwright set a $35.00 price objective on shares of Axovant Sciences and gave the stock a buy rating in a research note on Tuesday, February 14th. Piper Jaffray Companies set a $32.00 price target on shares of Axovant Sciences and gave the company a buy rating in a research report on Sunday, December 18th. Zacks Investment Research raised shares of Axovant Sciences from a sell rating to a hold rating in a research report on Thursday, March 9th. Cowen and Company began coverage on shares of Axovant Sciences in a research report on Friday, February 3rd. They set an outperform rating and a $22.00 price target on the stock. Finally, Robert W. Baird reaffirmed a positive rating and set a $29.00 price target on shares of Axovant Sciences in a research report on Tuesday, December 20th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and eight have assigned a buy rating to the company. Axovant Sciences presently has a consensus rating of Buy and a consensus price target of $27.04.
Shares of Axovant Sciences (NYSE:AXON) traded down 1.85% during midday trading on Friday, hitting $21.79. The stock had a trading volume of 294,243 shares. The stock has a 50 day moving average price of $21.01 and a 200-day moving average price of $15.06. Axovant Sciences has a 52 week low of $10.69 and a 52 week high of $25.18. The stock’s market capitalization is $2.16 billion.
ILLEGAL ACTIVITY WARNING: “Axovant Sciences’ (AXON) Outperform Rating Reiterated at Oppenheimer Holdings Inc.” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.com-unik.info/2017/05/19/axovant-sciences-axon-outperform-rating-reiterated-at-oppenheimer-holdings-inc-updated-updated-updated.html.
In other Axovant Sciences news, Director W Anthony Vernon acquired 53,937 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The stock was bought at an average cost of $18.54 per share, with a total value of $999,991.98. Following the acquisition, the director now owns 53,937 shares in the company, valued at $999,991.98. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider David Hung acquired 539,375 shares of the business’s stock in a transaction that occurred on Monday, April 17th. The stock was acquired at an average cost of $18.54 per share, with a total value of $10,000,012.50. Following the completion of the acquisition, the insider now owns 539,375 shares in the company, valued at approximately $10,000,012.50. The disclosure for this purchase can be found here. 3.10% of the stock is owned by corporate insiders.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Point72 Asset Management L.P. increased its position in Axovant Sciences by 1,718.3% in the first quarter. Point72 Asset Management L.P. now owns 209,100 shares of the biotechnology company’s stock valued at $3,124,000 after buying an additional 197,600 shares during the period. Bank of America Corp DE increased its position in Axovant Sciences by 38.9% in the first quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 2,072 shares during the period. Oppenheimer & Co. Inc. acquired a new position in Axovant Sciences during the first quarter valued at approximately $219,000. Geode Capital Management LLC increased its position in Axovant Sciences by 18.0% in the first quarter. Geode Capital Management LLC now owns 41,298 shares of the biotechnology company’s stock valued at $616,000 after buying an additional 6,308 shares during the period. Finally, Vanguard Group Inc. increased its position in Axovant Sciences by 3.9% in the first quarter. Vanguard Group Inc. now owns 131,681 shares of the biotechnology company’s stock valued at $1,968,000 after buying an additional 5,001 shares during the period.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
What are top analysts saying about Axovant Sciences Ltd? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Axovant Sciences Ltd and related companies.